Revenue: As of FY2026 Q1, the actual value is USD 117.7 M, beating the estimate of USD 104.46 M.EPS: As of FY2026 Q1, the actual value is USD 0.05, beating the estimate of USD -0.02.EBIT: As of FY2026 Q1, the actual value is USD 868 K.<h4>Segment Revenue</h4><ul><li>Total Revenue: CareDx, Inc. reported total revenue of $117.7 million for the three months ended March 31, 2026, an increase of 39% year-over-year compared to $84.7 million for the same period in 2025 .<ul><li>Testing Services Revenue: Increased by $29.5 million, or 48%, to $91.4 million for the three months ended March 31, 2026, from $61.9 million in the prior year . This was primarily driven by a 17% increase in testing services volume to approximately 54,900, including $17.7 million of increased net collections from prior periods, partially offset by a -$3.4 million reduction due to an increase in refund reserves . Testing services revenue constituted 78% of total revenue for the three months ended March 31, 2026, and 73% for the same period in 2025 .</li><li>Product Revenue: Decreased by -$0.5 million, or -4%, to $10.3 million for the three months ended March 31, 2026, compared to $10.8 million in the prior year, mainly due to lower sales of commercial NGS-based kitted solutions . Product revenue accounted for 9% of total revenue for the three months ended March 31, 2026, and 13% for the same period in 2025 .</li><li>Patient and Digital Solutions Revenue: Increased by $4.0 million, or 33%, to $16.0 million for the three months ended March 31, 2026, from $12.0 million in the prior year, primarily due to higher pharmacy sales and growth in digital solutions, particularly from expanded Ottr software customer base . This segment represented 14% of total revenue for both the three months ended March 31, 2026, and 2025 .</li></ul></li></ul><h4>Operational Metrics</h4><ul><li>Net Income (Loss): The company reported a net income of $2.8 million for the three months ended March 31, 2026, a significant improvement from a net loss of -$10.4 million for the same period in 2025 .</li><li>Operating Expenses: Total operating expenses increased by $18.4 million, or 19%, to $116.5 million for the three months ended March 31, 2026, compared to $98.1 million in the prior year .<ul><li>Cost of Testing Services: Increased by $2.0 million, or 13%, to $17.1 million for the three months ended March 31, 2026, compared to $15.1 million in 2025, mainly due to higher testing services volume, partially offset by efficiency measures .</li><li>Cost of Product: Decreased by -$0.8 million, or -13%, to $4.8 million for the three months ended March 31, 2026, from $5.6 million in 2025, primarily due to lower sales and improved manufacturing efficiencies .</li><li>Cost of Patient and Digital Solutions: Increased by $4.0 million, or 52%, to $11.7 million for the three months ended March 31, 2026, from $7.7 million in 2025, mainly due to increased cost of goods from the pharmacy business .</li><li>Research and Development (R&amp;D): Increased by $2.9 million, or 16%, to $21.4 million for the three months ended March 31, 2026, compared to $18.5 million in 2025, primarily due to increases in personnel-related costs and consulting/licensing expenses .</li><li>Sales and Marketing: Increased by $7.4 million, or 32%, to $30.4 million for the three months ended March 31, 2026, compared to $23.0 million in 2025, driven by higher personnel-related costs and marketing expenses .</li><li>General and Administrative (G&amp;A): Increased by $7.7 million, or 34%, to $30.5 million for the three months ended March 31, 2026, compared to $22.8 million in 2025, primarily due to increases in personnel-related costs, stock-based compensation, and legal/consulting expenses .</li><li>Litigation Settlement Expense: Decreased by -$4.8 million, or -89%, to $0.6 million for the three months ended March 31, 2026, compared to $5.4 million in 2025 . This decrease was mainly due to a $5.4 million settlement related to a Securities Class Action lawsuit in 2025, partially offset by a $0.6 million settlement for a Derivative Actions Lawsuit in 2026 .</li></ul></li><li>Income from Operations: The company reported an income from operations of $1.2 million for the three months ended March 31, 2026, compared to a loss from operations of -$13.4 million for the same period in 2025 .</li><li>Interest Income, net: Decreased by -$0.9 million for the three months ended March 31, 2026, compared to the same period in 2025, primarily due to a decrease in cash, cash equivalents, and marketable securities .</li><li>Other (Expense) Income, net: Decreased by -$0.6 million for the three months ended March 31, 2026, compared to the same period in 2025, primarily due to foreign exchange losses .</li></ul><h4>Cash Flow</h4><ul><li>Net Cash Provided by Operating Activities: $4.3 million for the three months ended March 31, 2026, compared to net cash used in operating activities of -$26.6 million for the same period in 2025 .</li><li>Net Cash Provided by Investing Activities: $11.1 million for the three months ended March 31, 2026, primarily from $54.7 million in maturities of marketable securities, partially offset by $39.9 million in purchases of marketable securities and $3.8 million in property and equipment additions . This compares to $1.3 million provided by investing activities in 2025 .</li><li>Net Cash Used in Financing Activities: -$2.9 million for the three months ended March 31, 2026, mainly due to -$2.5 million in taxes paid for net share settlements of restricted stock units and -$1.5 million for contingent consideration payments, partially offset by $1.0 million from employee stock purchase plan and $0.1 million from stock option exercises . This compares to -$0.6 million used in financing activities in 2025 .</li></ul><h4>Unique Metrics</h4><ul><li>Testing Services Volume: Approximately 54,900 tests for the three months ended March 31, 2026, an increase of 17% year-over-year .</li><li>Average Revenue per Test: Approximately $1,660, including $14 million in prior period revenue .</li><li>Cash, Cash Equivalents, and Marketable Securities: $198.1 million as of March 31, 2026, with no debt outstanding .</li></ul><h4>Future Outlook and Strategy</h4>CareDx, Inc. entered into a Purchase Agreement on April 15, 2026, to sell its kitted laboratory products business and related software for $170 million in cash, subject to customary adjustments . The company also agreed to acquire Naveris, Inc. for an aggregate of $160.0 million in cash at closing, plus up to $100.0 million in additional cash consideration contingent on achieving specified revenue-based milestones during fiscal years 2026 and 2027 . Additionally, CareDx, Inc.’s Board of Directors authorized a new share repurchase program on April 24, 2026, allowing for the repurchase of up to $100.0 million in common stock over two years, commencing April 30, 2026, with $12.2 million remaining available under the May 2025 Repurchase Program as of March 31, 2026 .

Caredex | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 117.7 M